The presence of minute amounts of chelators can help minimize the degradation of monoclonal antibodies.
Vikram Sadineni
Advertisement
Vikram Sadineni is senior research investigator, Department of Drug Product Science & Technology R&D, Bristol-Myers Squibb, New Brunswick, NJ 08903.
Articles by Vikram Sadineni
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
FDA Accepts BLA for Formycon and Zydus’ FYB206, the First Publicly Announced Keytruda Biosimilar Under Review
2
FDA Rare Disease Framework Initiative: What It Means for Drug and Biologic Development
3
FDA Expands Anktiva Approval to Papillary-Only BCG-Unresponsive Bladder Cancer
4
Lilly's Mirikizumab (Omvoh) Hits New IBD Remission Goals
5